Ascendiant Capital Markets Cuts PAVmed (NASDAQ:PAVM) Price Target to $19.00

PAVmed (NASDAQ:PAVM) had its target price cut by Ascendiant Capital Markets from $19.50 to $19.00 in a report released on Friday,Benzinga reports. They currently have a buy rating on the stock.

PAVmed Stock Up 0.0%

PAVmed stock opened at $0.63 on Friday. PAVmed has a 12 month low of $0.55 and a 12 month high of $1.90. The company’s fifty day simple moving average is $0.68 and its 200-day simple moving average is $0.71. The stock has a market cap of $10.80 million, a P/E ratio of -0.15 and a beta of 1.06.

Institutional Trading of PAVmed

A hedge fund recently raised its stake in PAVmed stock. First Manhattan CO. LLC. increased its holdings in PAVmed Inc. (NASDAQ:PAVM) by 16.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 700,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. First Manhattan CO. LLC. owned approximately 6.32% of PAVmed worth $439,000 at the end of the most recent reporting period. 19.93% of the stock is owned by institutional investors.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.